A recent randomized, double-blinded vehicle-controlled study demonstrated the importance of Elidel cream for the treatment of facial eczema in patients allergic to or intolerant of topical corticosteroids. The study enrolled 200 patients with mild to moderate atopic dermatitis, ages 12 and up across 29 centers. After 6 weeks, 46.5% of patients receiving Elidel were clear or almost clear versus only 16.2% of patients receiving placebo. Furthermore, Elidel demonstrated significant improvement in pruritus and in 46% of patients versus 19% receiving placebo, signs of skin atrophy were also improved. This study provides additional evidence of the importance of non-steroid topical treatments such as Elidel in the treatment of atopic dermatitis.
COPYRIGHT 2006 Journal of Drugs in Dermatology, Inc.
COPYRIGHT 2006 Gale Group
Contact
Home
A
E-Base